Aeglea BioTherapeutics, Inc. (AGLE) Misses Q3 EPS by 842c
Tweet
Share
E-mail
Get Alerts AGLE Hot Sheet
Join SI Premium – FREE
Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE) reported Q3 EPS of ($9.34), $8.42 worse than the analyst estimate of ($0.92).
For earnings history and earnings-related data on Aeglea BioTherapeutics, Inc. (AGLE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
- Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15
- Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
